In vitro studies have shown selpercatinib’s potent efficacy in suppressing the proliferation of diverse cancer cell lines with RET alterations, while in vivo models have demonstrated its ability to induce tumour regression (Figure 2). The gene discussed is RET; the disease is neoplasm.